CD19 and neoplasm: In this context, tumour infiltrating senescent T lymphocytes can affect B-cell (CD19+/CD20+) activation and their subsequent differentiation into CD27+/CD38+ cells, ultimately leading to a deficiency in antibody production and inefficient adaptive responses [86–88].